Active substance
Goserelin
- SFDA 2
- US FDA 3
- Health Canada 2
- NHS prices 2
- WHO EML 1
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ZOLADEX DEPOT 3.6MG S-C INJ SYRINGE | 3.6 mg | Implant · Subcutaneous use | 1 Pre-filled syringe | SAR 307.65 | NCE · Prescription | AstraZeneca UK Limited | Valid |
| Zoladex LA | 10.8 mg | Solution for injection · Subcutaneous use | 1 Pre-filled syringe | SAR 1292.10 | NCE · Prescription | AstraZeneca UK Limited | Valid |
Indications — CHI Daman Drug Formulary
BREAST CANCER; ENDOMETRIOSIS; MENSTRUAL DISORDERS; PROSTATE CANCER
US FDA United States — FDA approvals (Drugs@FDA)
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ZOLADEX | 02049325 | 3.6 MG | IMPLANT · SUBCUTANEOUS | TERSERA THERAPEUTICS LLC |
| ZOLADEX LA | 02225905 | 10.8 MG | IMPLANT · SUBCUTANEOUS | TERSERA THERAPEUTICS LLC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Goserelin 10.8mg implant pre-filled syringes | £235.00 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Goserelin 3.6mg implant pre-filled syringes | £94.50 | 1 pre-filled disposable injection | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.4. Hormones and antihormones · complementary
Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast; Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
Safety signals and safety-related labeling changes
- US FDA 6 May 2026 ZOLADEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 May 2026 ZOLADEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 May 2026 ZOLADEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 29 Sep 2017 PRAC signal: Thromboembolic events
Action for MAH: update of the product information: No - EMA PRAC 6 Mar 2014 PRAC signal: Long duration flushing and hyperhidrosis
Action for MAH: update of the product information: Yes - EMA PRAC 7 Nov 2013 PRAC signal: Long duration flushing and hyperhidrosis
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.